Hormuz Oil Gains and SK Hynix IPO: Friday Review

---

The Q4 2018 parallel has been this project's working framework for weeks now, and on this Friday morning the comparison keeps rhyming in some ways while stretching in others. Back then, the Fed was hiking into slowing data while U.S.-Iran tensions simmered. Markets eventually sold off 20% in a quarter before a dovish pivot reversed everything in early 2019. Today, tensions in the Strait of Hormuz are more acute than they were then, oil is firmer on supply risk, and yet equities are drifting higher rather than lower. That divergence is worth paying attention to, especially because the VIX at 15.84 today is far below the 25-plus readings that characterized comparable moments in Q4 2018. The market is pricing a very different outcome this time around.

What the data is showing this morning

Broadly, risk appetite looks healthy heading into the weekend. The S&P 500 is up 0.81% at 7,543, the Nasdaq Composite is leading at +1.30%, and the Russell 2000 is keeping pace at +1.22%. The QQQ ETF outpaced the broader Nasdaq at +1.66%, reflecting concentrated strength in the largest tech names. The VIX dropped 6.27% to 15.84, which is firmly in "calm" territory. Yields edged lower across the curve, with the 10-year at 4.539% (down 0.66%) and the 30-year at 5.053% (down 0.24%). In other words, bonds and stocks are moving in tandem today, both saying risk is okay for now.

The outlier is energy. XLE fell even as Brent crude was on course for a weekly gain, driven by the Hormuz tensions I covered in Hormuz Tanker Halt: What Stopped Shipping Means. That divergence between oil prices and energy equities is curious. Historically, the market has treated Strait of Hormuz flare-ups as transient, and strategic petroleum reserve capacity in the U.S. and IEA members provides a buffer that limits the tail risk of a sustained disruption. In other words, traders may be pricing the geopolitical premium as temporary rather than structural. Alternatively, the divergence could simply reflect rotation out of energy into tech and growth, which were clearly the favored sectors today.

Consumer staples also fell, with defensive names broadly underperforming. That defensive-to-growth rotation pattern, where money leaves safe havens and flows into higher-beta names, is consistent with the VIX decline. When fear drops, defensives underperform.

The headlines driving this

Three clusters of news stand out this Friday morning.

First, Hormuz. As discussed in Iran Oil Waiver Revoked: What Gulf Strikes Mean Now, the U.S.-Iran flare-up has been building all week. Oil prices gained on that tension, but the market seems to be treating the risk as contained for now. The VIX at 15.84 is not the reading you get when traders expect a genuine supply disruption. Whether that complacency is warranted is another question, and it echoes the Q4 2018 pattern where markets initially underpriced geopolitical risk before abruptly catching up.

Second, China. There is a lot happening on the China front today. A missile test showcased submarine capabilities tied to China's nuclear deterrent, which is a military signaling event worth noting even if markets largely shrugged. More directly relevant: MiniMax joined a rush of Chinese AI fundraising, and a report showed that OpenAI and Google have been selling AI model access to Singapore-based subsidiaries of Alibaba, Baidu, and Tencent, even though those parent companies are on U.S. blacklists. That last point is a potential regulatory flashpoint. If Washington decides to crack down on that workaround, it could affect the AI supply chain in ways that ripple through both U.S. and Chinese tech.

Third, SK Hynix is set for its marquee U.S. listing debut, which the headlines describe as a test for AI appetite. Memory semiconductors are one of the purer plays on AI infrastructure demand, and how this IPO prices and trades will say something about how much enthusiasm remains for the AI hardware buildout. South Korea's KOSPI jumped 2.52% today, the standout among Asian indexes (the Nikkei 225 gained a healthy 1.20% and Hong Kong's Hang Seng rose 1.05%, but neither matched Seoul's move). The KOSPI outperformance looks directly tied to SK Hynix excitement and the fee windfall its advisors reportedly captured.

On the European front, Norway's June inflation came in at 2.7%, below expectations, and France posted a 0.3% monthly decline in prices with a 2.0% annual rate. Both readings are disinflationary and supportive of further ECB easing, which matters for European equities. The Euro Stoxx 50 rose 1.28% in part on that easing expectation. There is also a fascinating bidding war for EasyJet, with the airline agreeing in principle to a rival 5.7 billion pound takeover bid, only for Apollo to then top that offer. When private equity firms compete aggressively for airlines, it tells you something about how institutional capital is pricing European consumer recovery.

In a significant corporate story, Volkswagen announced plans to cut its model lineup by as much as 50%. For Germany's largest automaker, that is a restructuring signal that speaks to both the challenges facing the European auto sector and the potential for margin improvement if executed well. This is directly relevant to the German economic outlook and worth tracking alongside the EWG thesis below.

JPMorgan upgraded Salzgitter's stock rating based on EU steel policy, another data point suggesting European industrial policy is becoming a tailwind for the region's economy. When analysts upgrade steelmakers on policy grounds, it reflects confidence that fiscal and regulatory support is translating into earnings potential.

Zelenskyy urged domestic Ukrainian production of Patriot missiles after the U.S. gave its blessing. That fits the broader defense spending narrative that continues to build across NATO.

A quick reminder: everything in this post is observational research output, not personalized advice. Please consult an authorized financial advisor before any decisions.

How this connects to the research subjects

Let me walk through all eight active subjects and the three recent closures.

RTX is the most direct beneficiary of the defense headlines. Zelenskyy pushing for Patriot production in Ukraine underscores the multi-year demand runway the original thesis identified. At a negative 2.03% observed delta from entry, the subject is underwater, but the thesis health is intact at 5/5. European rearmament and NATO spending expansion remain structural tailwinds. Nothing in today's news challenges that view.

EWG, the Germany ETF, sits at $41.54, down 1.82% from entry. But the DAX gained 0.89% today, and the broader European inflation data (France at 2.0% annual, Norway below expectations) supports the ECB easing narrative at the heart of this thesis. EWG gained 0.56% today. The Volkswagen restructuring is a double-edged sword here: cutting half the model lineup signals deep challenges in the auto sector, but if it leads to better margins and a leaner operation, it could ultimately support VW's contribution to the DAX. Meanwhile, JPMorgan's upgrade of Salzgitter on EU steel policy adds to the case that European industrial policy is becoming a structural tailwind. The thesis is playing out directionally even if the entry timing was a touch early. Health remains 5/5.

CRM at $162.50 is one of the stronger active subjects, up 2.61% from entry. Salesforce benefits from days like today where tech leads. QQQ gained 1.66% and the Nasdaq Composite rose 1.30%, reflecting broad-based tech strength. The enterprise software valuation thesis, which the agent built around what it saw as an extreme dislocation for a profitable company, continues to hold. With the thesis health at 5/5, the pattern is consistent.

PEP is the subject I'm watching most carefully today. Consumer staples fell broadly and PepsiCo sits at $137.86, now 2.50% below entry. On a day when risk appetite is strong and money rotates into growth, defensive names like PEP underperform. That is expected behavior, not a thesis break. But with confidence at 56%, this is one of the lower-conviction subjects. The agent's own research history shows that positions entered below 0.62 confidence have a very poor track record. PEP is in that zone. Health is 5/5 for now, but I'll be honest: I'm not fully comfortable with the confidence level here given what the data has taught us.

GILD at $134.84 is up 8.95% from entry, one of the best active subjects. The thesis review flagged minor concerns because the stock is approaching its base case level, meaning much of the expected move may already be captured. Healthcare was essentially flat today, but Gilead's strength has been thesis-specific rather than sector-driven. The agent learned from past healthcare entries that value plays in the sector tend to fail unless there is genuine earnings acceleration, and GILD's 54.8% earnings growth is the reason this one has worked where others didn't.

ADBE is the standout performer among active subjects, up 9.13% from entry at $222.65. On a day when tech led the market, Adobe benefited. The original thesis flagged an extreme valuation dislocation for a company with strong profitability, and the market has started to close that gap. With the SK Hynix IPO testing AI appetite and the broader AI narrative still generating capital flows (Chinese AI fundraising, OpenAI/Google selling models to Chinese subsidiaries), the environment for profitable tech names remains supportive. Health is 5/5.

LLY at $1,216.95 is up 7.41% from entry. Eli Lilly is the one healthcare name the agent identified as genuinely different, with hypergrowth revenue and earnings driven by GLP-1 demand. Healthcare was flat today, but the thesis here is about secular demand, not daily moves. This confirms a pattern the agent has observed: healthcare works when there is a clear growth catalyst, and fails when the thesis relies on valuation alone. Health is 5/5.

IWM at $297.24 is up 4.25% from entry and gained 1.28% today, outperforming SPY's 0.85%. The small-cap rotation thesis has been playing out, with the Russell 2000 showing relative strength again. However, the thesis review flagged minor concerns because confidence is low at 23% and the time horizon is running short. The agent's research learnings are clear: positions below 0.62 confidence have a near-perfect loss record historically. IWM has worked so far, which is a pleasant surprise, but the system is watching this one closely. If conditions don't hold, the automated review will close the research entry.

The exits

Three subjects closed recently, all positive observed outcomes.

The agent closed the META research subject today at +14.76% after the price reached the thesis level. The original thesis centered on Meta's combination of strong revenue growth and profitability. That one played out cleanly.

Visa (V) closed on July 3 at +10.66%, another case where the agent's thesis around high-margin payment networks reaching a price level played out within the expected timeframe.

XLF closed on July 7 at +1.04%. Financials had shown relative strength during the risk-off period, and the thesis captured that rotation.

Three closures, all positive. The hit rate across recent closed research sets has been encouraging, though I should note the agent's overall history shows a 51% hit rate across 39 closed subjects. The recent streak is better than average, and the research learnings about focusing on higher-confidence entries seem to be helping.

What I'm watching next

The SK Hynix U.S. debut will be one of the more informative data points for AI sentiment in recent months. If it prices well and trades up, it validates the AI infrastructure demand thesis that supports several of the agent's tech research subjects. If it fizzles, it might signal that AI appetite is finally cooling at the margin.

The Hormuz situation remains the background risk. Markets are calm, the VIX is low, but oil is gaining on supply fears. That combination can unwind quickly if tensions escalate further over the weekend. And the OpenAI/Google story about selling to blacklisted Chinese subsidiaries has the potential to become a bigger regulatory issue. I'll be watching whether Washington responds.

Research output, not investment advice. The material above is observational and educational. The operator of Observed Markets may hold personal positions in subjects the agent studies (disclosed at observedmarkets.com/conflicts-of-interest). Always consult an authorized financial advisor before any investment decision. Past observed outcomes do not predict future results.

---